Highly active antiretroviral treatment in countries with very limited resources: Do we have cheaper alternatives?

International Journal of STD and AIDS

Volumn 14, Issue 1, 2003, Pages 1-5

  Colebunders, R ^a,b   Florence, E ^a   Lynen, L ^a,c   Bouckenooghe, A ^d  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c Sihanouk Hospital Center of HOPE   (Cambodia)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHLOROQUINE; CYCLOSPORIN A; DIDANOSINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HYDROXYUREA; INTERLEUKIN 2; MYCOPHENOLIC ACID; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CLINICAL TRIAL; DEVELOPING COUNTRY; DRUG COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; INFECTION; MAINTENANCE THERAPY; MEDICAL ETHICS; PANCREATITIS; PRIORITY JOURNAL; REVIEW; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEVELOPING COUNTRIES; HIV INFECTIONS; HUMANS;

EID: 0037241549     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/095646203321043174     Document Type: Review

References (49)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60
2. Steinbrook R. Beyond Barcelona - The global response to HIV. N Engl J Med 2002;347:553-4
3. Miller V. Structured treatment interruptions in antiretroviral management of HIV-1. Curr Opin Infect Dis 2001;14:29-37
4. Ruiz L, Carcelain G, Martinez-Picado J, et al. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS 2001;15:F19-27
5. Lori F. Stimulating the immune system against HIV: structured treatment interruptions. IAPAC sessions 2001, July 18-19, IAPAC Mon 2001;7:228-32
6. Martinez-Picado J, Morales-Lopetegi K, Wrin T, et al. Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS 2002;16:895-9
7. Hirschel B. Planned interruptions of anti-HIV treatment. Lancet Infect Dis 2001;1:53-9
8. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA panel. JAMA 2000;283:381-90
9. Department of Health and Human Services/Henry J Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. February 4, 2002. Available online at http://www.hivatis.org/guidelines/adult/Feb04_02/AdultGdl.pdf
10. Oxenius A, Price DA, Easterbrook PJ, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci USA 2000;97:3382-7
11. Bisset LR, Cone RW, Huber W, et al. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study. AIDS 1998;12:2115-23
12. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998;339:33-9
13. Rosenberg E, Altfelt M, Poon SH. Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407:523-6
14. Schacker R, Litle S, Connick E. Rapid accumulation of Human Immunodeficiency Virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: implications for timing of antiretroviral therapy. J Infect Dis 2000;181:354-7
15. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings. Guidelines for a public health approach. April 2002, 1-31
16. Daar ES, Little S, Pitt J, et al. Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med 2001;134:25-9
17. Working group on Antiretroviral Therapy and Medical Management of HIV Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infections. December 14, 2001. Available online at http://www.hivatis.org/guidelines/Pediatric/Dec12_01/peddec.pdf
18. Reijers MHE, Weverling GJ, Jurriaans S. The ADAM study continued: maintenance therapy after 50 weeks of induction therapy. AIDS 2001;15:129-31
19. Havlir DV, Marschner IC, Hirsch MS. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med 1998;339:1261-8
20. Pialoux G, Raffi F, Brun-Vezinet F, et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team. N Engl J Med 1998;339:1269-76
21. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286:2568-77
22. Phillips AN, Staszewski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001;286:2560-7
23. Yeni PG, Hammer SM, Cooper DA, et al. Antiretroviral treatment for adult HIV infection in 2002. Updated recommendations of the International AIDS Society-USA Panel. JAMA 2002;2888:222-35
24. Donehower RC. An overview of the clinical experience with hydroxyurea. Semin Oncol 1992;19(Suppl 9):11-19
25. Rutschemann OT, Opravil M, Iten A, et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS 1998;12:F71-7
26. Goodrich J, Khardori N. Hydroxyurea toxicity in human immunodeficiency virus-positive patients. Clin Infect Dis 1999;29:692-3
27. Sperber K, Kalb TH, Stecher VJ, Banerjee R, Mayer L. Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. AIDS Res Hum Retroviruses 1993;9:91-8
28. Boelaert JR, Sperber K, Piette J. Chloroquine exerts an additive in vitro anti-HIV type 1 effect when associated with didanosine and hydroxyurea. AIDS Res Hum Retroviruses 1999;15:1241-7
29. Pardridge WM, Yang J, Diagne A. Chloroquine inhibits HIV-1 replication in human peripheral blood lymphocytes. Immunol Lett 1998;64:45-7
30. Fryauff DJ, Cryz SJ, Widjaja H, et al. Humoral immune response to tetanus-diphtheria vaccine given during extended use of chloroquine of primaquine malaria chemoprophylaxis. J Infect Dis 1998;177:1762-5
31. Boelaert JR, Weinberg GA, Weinberg ED. Altered iron metabolism in HIV infection: mechanisms, possible consequences, and proposals for management. Infect Agents Dis 1996;5:36-46
32. Mazzolla R, Barluzzi R, Brozzetti A, et al. Enhanced resistance to Cryptococcus neoformans infection induced by chloroquine in a murine model of meningoencephalitis. Antimicrob Agents Chemother 1997;41:802-7
33. Hoffman IF, Jere CS, Taylor TE. The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. AIDS 1999;13:487-94
34. Steketee RW, Wirima JJ, Bloland PB, et al. Impairment of a pregnant woman's acquired ability to limit Plasmodium falciparum by infection with human immunodeficiency virus type-1. Am J Trop Med Hyg 1996;55(Suppl 1):42-9
35. Verhoef H, Veenemans J, West CE. HIV-1 infection and malaria parasitaemia. Lancet 2001;357:232-3
36. Boelaert JR, Yaro S, Augustijns P, et al. Chloroquine accumulates in breast-milk cells: potential impact in the prophylaxis of postnatal mother-to-child transmission of HIV-1. AIDS 2001;15:2205-7
37. Paton NI, Aboulhab J, Karim F. Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1. Lancet 2002;359:1667-8
38. Shanmuganathan K, Koudriakova T, Nampalli S, et al. Enhanced brain delivery of an anti-HIV nucleoside 2′-F-ara-ddl by xanthine oxidase mediated biotransformation. J Med Chem 1994;37:821-7
39. Zalma A, von Moltke LL, Granda BW, Harmatz JS, Shader RI, Greenblatt DJ. In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. Biol Psychiatry 2000;47:655-61
40. Milan EP, Burattini MN, Kallas EG, Fischmann O, Costa PR, Colombo AL. Azole resistance among oral Candida species isolates from AIDS patients under ketoconazole exposure. Diagn Microbiol Infect Dis 1998;32:211-16
41. Jin X, Ramanathan M Jr, Barsoum S. Safety and immunogenicity study of vCP1452/rgp 160 therapeutic vaccines in patients treated with HAART for over two years. Program and abstracts of the 8th Conference on Retroviruses and opportunistic infections. Chicago, Illinois 2001. Abstract 21
42. Rizzardi GP, Capiluppi B, Chave JP. Activity of cyclosporin A in combination with highly active antiretroviral therapy in primary HIV-1 infection. AIDS 2000;14:S9
43. 3. ACTG 328 - results at 60 weeks. AIDS 2000;14:S9
44. Emery S, Capra WB, Cooper DA, et al. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. J Infect Dis 2000;182:428-34
45. Heredia A, Margolis D, Oldach D, Hazen R, Le N, Redfield R. Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1. J Acquir Immune Defic Syndr 1999;22:406-7
46. Weissman D, Barker TD, Fauci AS. The efficiency of acute infection of CD4+ T cells is markedly enhanced in the setting of antigen-specific immune activation. J Exp Med 1996;183:687-92
47. Bentwich Z, Kalinkovich A, Weisman Z, Borkow G, Beyers N, Beyers AD. Can eradication of helminthic infections change the face of AIDS and tuberculosis? Immunol Today 1999;20:485-7
48. Wiktor SZ, Sassan-Morokro M, Grant AD, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial. Lancet 1999;353:1469-75
49. National Bioethics Advisory Commission. Ethical and Policy Issues in International Research: Clinical Trials in Developing Countries. Volume II: Commisssioned papers and staff analysis, Bethesda, Maryland, May 2001. Available online at http://www.bioethics.georgetown.edu/nbac/clinical/Vol2.pdf